Sonnet BioTherapeutics Holdings, Inc. (SONN) shares plummeted 19.9% on Wednesday after the company announced a 1-for-8 reverse stock split, aimed at meeting Nasdaq’s minimum bid price requirement. The move will reduce the company’s outstanding shares, but investors are left wondering if it’s a sign of future success or a desperate attempt to stay afloat.